Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00612157 · ClinicalTrials.gov registry record · Phase 4
Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)
A Phase 4 study, sponsored by Walter Reed Army Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 154
- Enrollment target
NCT00612157 is a Phase 4 study that has completed, run by Walter Reed Army Medical Center. The registered enrollment target is 154 participants.
The verdict
NCT00612157, a Phase 4 study, has completed, sponsored by Walter Reed Army Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 154 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of Eszopiclone in improving short and intermediate-term compliance with continuous positive airway pressure (CPAP) in patients newly diagnosed with obstructive sleep apnea (OSA).
Interventions
- DRUG Placebo control
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00612157
The ClinicalTrials.gov registry entry for NCT00612157 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Walter Reed Army Medical Center, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.
NCT00612157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00612157 about?
NCT00612157 is a clinical study titled "Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)". The purpose of this study is to assess the efficacy of Eszopiclone in improving short and intermediate-term compliance with continuous positive airway pressure (CPAP) in patients newly diagnosed with obstructive sleep apnea (OSA).
What is the current status of trial NCT00612157?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 154 participants. The study started on 2008-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00612157?
The interventions under investigation include: Placebo control (DRUG), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00612157?
This trial is sponsored by Walter Reed Army Medical Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.